Advertisement
Research Article

Identification of Compounds with Anti-Proliferative Activity against Trypanosoma brucei brucei Strain 427 by a Whole Cell Viability Based HTS Campaign

  • Melissa L. Sykes equal contributor,

    equal contributor Contributed equally to this work with: Melissa L. Sykes, Jonathan B. Baell

    Affiliation: Discovery Biology, Eskitis Institute for Cell and Molecular Therapies, Griffith University, Nathan, Queensland, Australia

    X
  • Jonathan B. Baell equal contributor,

    equal contributor Contributed equally to this work with: Melissa L. Sykes, Jonathan B. Baell

    Affiliations: The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia, Department of Medical Biology, The University of Melbourne, Parkville, Victoria, Australia, Department of Medicinal Chemistry, Faculty of Pharmacy and Pharmaceutical Sciences, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia

    X
  • Marcel Kaiser,

    Affiliations: Swiss Tropical and Public Health Institute, Basel, Switzerland, University of Basel, Basel, Switzerland

    X
  • Eric Chatelain,

    Affiliation: Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland

    X
  • Sarah R. Moawad,

    Affiliations: The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia, Department of Medical Biology, The University of Melbourne, Parkville, Victoria, Australia

    X
  • Danny Ganame,

    Affiliations: The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia, Department of Medical Biology, The University of Melbourne, Parkville, Victoria, Australia

    X
  • Jean-Robert Ioset,

    Affiliation: Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland

    X
  • Vicky M. Avery mail

    v.avery@griffith.edu.au

    Affiliation: Discovery Biology, Eskitis Institute for Cell and Molecular Therapies, Griffith University, Nathan, Queensland, Australia

    X
  • Published: November 29, 2012
  • DOI: 10.1371/journal.pntd.0001896

About the Authors

Melissa L. Sykes, Vicky M. Avery
Discovery Biology, Eskitis Institute for Cell and Molecular Therapies, Griffith University, Nathan, Queensland, Australia
Jonathan B. Baell, Sarah R. Moawad, Danny Ganame
The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
Jonathan B. Baell, Sarah R. Moawad, Danny Ganame
Department of Medical Biology, The University of Melbourne, Parkville, Victoria, Australia
Jonathan B. Baell
Department of Medicinal Chemistry, Faculty of Pharmacy and Pharmaceutical Sciences, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia
Marcel Kaiser
Swiss Tropical and Public Health Institute, Basel, Switzerland
Marcel Kaiser
University of Basel, Basel, Switzerland
Eric Chatelain, Jean-Robert Ioset
Drugs for Neglected Diseases initiative (DNDi), Geneva, Switzerland

Corresponding Author

Email: v.avery@griffith.edu.au

Competing Interests

The authors have declared that no competing interests exist.

Author Contributions

Conceived and designed the experiments: VMA MLS JBB MK. Performed the experiments: MLS JBB DG MK. Analyzed the data: MLS JBB MK DG SRM. Contributed reagents/materials/analysis tools: VMA JBB JRI EC MK DG. Wrote the paper: MLS VMA JBB EC JRI.